Sarepta Therapeutics Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (50)

Latest Posts

About This Stock More About This Stock
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
Article By: T.J. Hayes
Monday, September 9, 2019 7:36 PM EDT
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB
Read
5 Monster Stocks To Watch For Wednesday, August 21
Article By: Michael J. Kramer
Wednesday, August 21, 2019 4:32 AM EDT
There is the possibility we continue to drift lower on today, as the index works its way towards 2890, in an attempt to refill a gap.
In this article: AMD, JD, BAC, AMZN, SRPT Also: FXI, SPY, VXX
Read
3 Bull Stocks Driving Analysts Crazy
Article By: TipRanks
Thursday, September 27, 2018 9:22 AM EDT
Take a closer look at these three stocks.
In this article: SRPT, BX, AMZN
Read
Sarepta Price Target Raised To $168 From $83 At Piper Jaffray
Article By: The Fly
Wednesday, June 20, 2018 7:15 AM EDT
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics to $168 from $83 after the company presented Phase I/II data on three Duchenne muscular dystrophy boys receiving its micro-dystrophin gene therapy.
In this article: SRPT
Read
Biotech Stocks Emerge Unscathed And Ready To Go
Article By: Tarun Chandra, CFA
Friday, May 18, 2018 8:41 PM EDT
The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.
In this article: CVS, MRK, IBB, INCY, ESRX, XBI, ARNA, ECYT, IMMU, IRWD, DVAX, SUPN, SRPT, AGIO, QURE, HRTX, LOXO, ATRA, BGNE, ADAP, CRSP, CBIO, GTHX, MRTX
Read

PARTNER HEADLINES

Latest Tweets for $SRPT

No tweets yet!

$SRPT

Why Sarepta Therapeutics Inc Looks On Track For A Second DMD Approval
Carol Klein 10/11/2017 1:39:12 PM

Looks promising, thanks. $SRPT.

1 to 1 of 1 comments